Tripokin (IL2-L19-TNF) / Philogen - LARVOL DELTA

Tripokin: A multi-specific immunocytokine for cancer immunotherapy. (PubMed, Int J Cancer) - "In addition, the combination with immune checkpoint inhibitors further boosted the therapeutic efficacy of our molecule. Tripokin represents a promising clinical candidate for the simultaneous delivery of interleukin-2 and tumor necrosis factor to neoplastic sites."

IO biomarker • Journal • Oncology • EDB-FN • IL2 • TNFA

Tripokin: potential best-in-class for tumor targeted interleukin-2 (IL2) potentiated by tumor necrosis factor (TNF) (AACR 2023) - "Compared to the previous product, Tripokin showed a favorable pharmacokinetic profile in monkey, an excellent localization to neoplastic lesions in mice and was easier to formulate for further clinical applications. When tested in tumor bearing mice, Tripokin revealed a superior anti-cancer activity compared to other IL2-based products.The results obtained in this work provided a rationale for future clinical translation activities using Tripokin as potential best-in-class tumor targeted IL2 product."

IO biomarker • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor • CD4 • CD8 • IL2 • TNFA